In this regard, a pilot clinical trial has employed CAR-DCs containing an scFv domain targeting EphA2 antigen, loaded with TP53 mutant peptide (TP53-EphA-2-CAR-DC) in combination with ICIs to assess the safety and antitumor effects in subjects with local advanced/metastatic solid tumors or relapsed/refractory (R/R) lymphomas (NCT05631886). Here, EPHA2 is linked to lymphoma.